Seeking Alpha EN

Sutro Biopharma GAAP EPS of -$22.49 misses by $7.28, revenue of $102.48M beats by $3.3M

Mar 23, 2026 &03142323202631; 20:14 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -65/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Sutro Biopharma reported GAAP EPS of -$22.49, missing expectations by $7.28, though revenue of $102.48M exceeded estimates by $3.3M. The significant EPS miss reflects substantial operating losses despite revenue beat, indicating profitability challenges persist.

AI CONFIDENCE

75% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

SUTRO

SUTROStock

Expected to decline

Large EPS miss of $7.28 signals deep losses; revenue beat insufficient to offset profitability concerns and negative guidance implications

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Avoid long positions; consider short-term bearish bias. Monitor guidance and cash runway disclosures. Revenue growth alone insufficient for biotech without profitability trajectory or clear clinical catalysts.

KEY SIGNALS

Massive negative EPS (-$22.49) indicates severe cash burnRevenue beat cannot offset operating lossesBiotech company still unprofitable at scaleMarket likely to focus on path to profitability rather than top-line growth

SECTORS INVOLVED

BiotechnologyHealthcarePharmaceuticals

Analysis generated on Mar 23, 2026 at 20:57 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Sutro Biopharma GAAP EPS of -$22.49 misses by $7.28, revenue of $102.48M beats by $3.3M

RELATED INTELLIGENCE